stockrow
Friday 6 November 2026
Export CPIX’s income statement to Excel — free account
Cumberland Pharmaceuticals Inc.
CPIX Healthcare Drug Manufacturers Specialty & Generic
Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Revenue
- −98.5%
- EPS
- −480.0%
- Free cash flow
- −82.8%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
5.24
0.23
+4.59%
Follow CPIX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.13 | 1.33 | 1.16 | 3.10 | |
P/FCF ratio |
7.00 | 12.45 | 39.28 | 168.58 | |
P/Operating CF |
249.32 | 19,707.63 | 125.63 | 575.14 | |
P/B ratio |
1.81 | 2.41 | 2.28 | 5.68 | |
Price to Tangible BV |
4.73 | 2.41 | 6.40 | 5.69 | |
EV/Sales |
1.01 | 1.30 | 1.14 | 3.31 | |
EV/EBITDA |
0.00 | 42.88 | 0.00 | 0.00 | |
EV/Operating CF |
6.12 | 11.76 | 33.75 | 138.82 | |
EV/FCF |
6.27 | 12.21 | 38.74 | 179.83 | |
Quick Ratio |
1.05 | 0.77 | 0.73 | 0.49 | |
Current Ratio |
1.23 | 1.01 | 0.95 | 0.96 | |
Net Debt/EBITDA |
(9.39) | (3.04) | 3.11 | 0.88 | |
Debt/Assets |
7.95% | 6.82% | 7.38% | 0.00% | |
Debt/Equity |
0.20 | 0.21 | 0.25 | 0.00 | |
Asset Turnover |
0.58 | 0.58 | 0.60 | 0.48 | |
Operating CF/Net income |
(0.10) | 0.00 | (0.12) | (0.04) | |
Capex/Depreciation |
(0.02) | (0.04) | (0.01) | 0.02 | |
Interest Coverage |
(17.92) | 4.51 | (36.47) | (4,515.00) | |
Research and Development Expense of Revenue |
15.12% | 15.94% | 15.97% | 463.78% | |
Selling, General and Administrative Expense of Revenue |
84.49% | 107.37% | 83.44% | 1,530.09% | |
Intangible Assets out of Total Assets |
0.24 | 0.00 | 0.19 | 0.00 | |
Share Based Compensation of Revenue |
0.98% | 1.26% | 1.17% | 46.79% | |
Graham Net Nets |
(0.22) | (0.26) | (0.35) | (0.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.69%) | (4.77%) | (15.08%) | (11.27%) | |
Free Cash Flow Yield |
14.29% | 8.03% | 2.55% | 0.59% | |
Revenue per Share |
0.55 | 0.92 | 0.61 | 0.01 | |
Operating CF per Share |
0.01 | 0.00 | 0.03 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | 0.00 | 0.02 | 0.01 | |
Cash per Share |
1.02 | 0.77 | 0.74 | 0.26 | |
Shareholders Equity per Share |
1.72 | 1.65 | 1.42 | 1.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.72 | 1.65 | 1.42 | 1.14 | |
Free Cash Flow |
0.13 | (0.04) | 0.37 | 0.14 | |
Working Capital |
5.63 | 0.32 | (1.70) | (1.55) | |
Capital Expenditures |
(0.05) | (0.04) | (0.02) | (0.03) | |
Net Current Asset Value |
(10.16) | (15.22) | (16.90) | (12.13) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.16 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.87 | 14.32 | 12.37 | 11.87 | |
Average Payables |
12.95 | 16.24 | 15.23 | 16.50 | |
Average Inventory |
3.72 | 2.01 | 4.78 | 1.63 | |
Average Assets |
71.32 | 76.20 | 70.47 | 65.39 | |
Average Common Equity |
25.14 | 23.55 | 24.82 | 22.39 |
Columns are period end dates · fundamentals updated 26 Oct 2026